169 related articles for article (PubMed ID: 37903331)
1. Cell-Specific Degradation of Histone Deacetylase Using Warhead-Caged Proteolysis Targeting Chimeras.
Jia Q; Zhang Y; Liu F; Dong W; Zhu L; Wang F; Jiang JH
Anal Chem; 2023 Nov; 95(45):16474-16480. PubMed ID: 37903331
[TBL] [Abstract][Full Text] [Related]
2. The application of PROTAC in HDAC.
Chen S; Zheng Y; Liang B; Yin Y; Yao J; Wang Q; Liu Y; Neamati N
Eur J Med Chem; 2023 Nov; 260():115746. PubMed ID: 37607440
[TBL] [Abstract][Full Text] [Related]
3. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead.
Zhang P; Wang W; Guo M; Zhou L; Dong G; Xu D; Sheng C
Bioorg Med Chem Lett; 2023 Aug; 92():129393. PubMed ID: 37369332
[TBL] [Abstract][Full Text] [Related]
5. Advances in the Design and Development of PROTAC-mediated HDAC Degradation.
Rodrigues DA; Roe A; Griffith D; Chonghaile TN
Curr Top Med Chem; 2022 Mar; 22(5):408-424. PubMed ID: 34649488
[TBL] [Abstract][Full Text] [Related]
6. Designing HDAC-PROTACs: lessons learned so far.
Fischer F; Alves Avelar LA; Murray L; Kurz T
Future Med Chem; 2022 Jan; 14(3):143-166. PubMed ID: 34951318
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting Chimeras.
Darwish S; Heimburg T; Ridinger J; Herp D; Schmidt M; Romier C; Jung M; Oehme I; Sippl W
Methods Mol Biol; 2023; 2589():179-193. PubMed ID: 36255625
[TBL] [Abstract][Full Text] [Related]
8. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8.
Sun Z; Deng B; Yang Z; Mai R; Huang J; Ma Z; Chen T; Chen J
Eur J Med Chem; 2022 Sep; 239():114544. PubMed ID: 35759908
[TBL] [Abstract][Full Text] [Related]
9. Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
Cao F; de Weerd S; Chen D; Zwinderman MRH; van der Wouden PE; Dekker FJ
Eur J Med Chem; 2020 Dec; 208():112800. PubMed ID: 32971411
[TBL] [Abstract][Full Text] [Related]
10. Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection.
Zahid S; Ali Y; Rashid S
J Biomol Struct Dyn; 2023; 41(23):14566-14581. PubMed ID: 36841549
[TBL] [Abstract][Full Text] [Related]
11. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity.
Darwish S; Ghazy E; Heimburg T; Herp D; Zeyen P; Salem-Altintas R; Ridinger J; Robaa D; Schmidtkunz K; Erdmann F; Schmidt M; Romier C; Jung M; Oehme I; Sippl W
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886887
[TBL] [Abstract][Full Text] [Related]
13. Discovery of highly potent HDAC8 PROTACs with anti-tumor activity.
Zhao C; Chen D; Suo F; Setroikromo R; Quax WJ; Dekker FJ
Bioorg Chem; 2023 Jul; 136():106546. PubMed ID: 37098288
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs).
Baker IM; Smalley JP; Sabat KA; Hodgkinson JT; Cowley SM
Biochemistry; 2023 Feb; 62(3):645-656. PubMed ID: 35948047
[TBL] [Abstract][Full Text] [Related]
16. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
17. Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment.
Xie B; Xu B; Xin L; Wei Y; Guo X; Dong C
Bioorg Chem; 2023 Aug; 137():106590. PubMed ID: 37163809
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
19. Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues.
Shi S; Du Y; Zou Y; Niu J; Cai Z; Wang X; Qiu F; Ding Y; Yang G; Wu Y; Xu Y; Zhu Q
J Med Chem; 2022 Mar; 65(6):5057-5071. PubMed ID: 35175763
[TBL] [Abstract][Full Text] [Related]
20. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
Yao R; Luo T; Wang M
Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
